Helen M Wilfehrt

All Stories

1. 
   Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • November 2025, American Association for Cancer Research (AACR)

   Helen M Wilfehrt, MD lawrence i karsh

2. 
   Supplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • November 2025, American Association for Cancer Research (AACR)

   Helen M Wilfehrt, MD lawrence i karsh

3. 
   Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • November 2025, American Association for Cancer Research (AACR)

   Helen M Wilfehrt, MD lawrence i karsh

4. 
   Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • November 2025, American Association for Cancer Research (AACR)

   Helen M Wilfehrt, MD lawrence i karsh

5. 
   Data from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • September 2024, American Association for Cancer Research (AACR)

   MD lawrence i karsh, Helen M Wilfehrt

6. 
   Data from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • September 2024, American Association for Cancer Research (AACR)

   MD lawrence i karsh, Helen M Wilfehrt

7. 
   Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • September 2024, American Association for Cancer Research (AACR)

   MD lawrence i karsh, Helen M Wilfehrt

8. 
   Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • September 2024, American Association for Cancer Research (AACR)

   MD lawrence i karsh, Helen M Wilfehrt

9. 
   Supplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • September 2024, American Association for Cancer Research (AACR)

   MD lawrence i karsh, Helen M Wilfehrt

10. 
    Supplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • September 2024, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

11. 
    Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • September 2024, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

12. 
    Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • September 2024, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

13. 
    Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • September 2024, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

14. 
    Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • September 2024, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

15. 
    Data from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

16. 
    Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

17. 
    Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

18. 
    Supplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

19. 
    Supplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

20. 
    Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

21. 
    Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

22. 
    Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

23. 
    Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

24. 
    Data from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

25. 
    Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

26. 
    Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

27. 
    Supplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

28. 
    Supplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

29. 
    Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

30. 
    Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

31. 
    Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

32. 
    Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

33. 
    Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • Clinical Cancer Research, April 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

34. 
    A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer

    Article • Advances in Therapy, October 2020, Springer Science + Business Media

    Helen M Wilfehrt